نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

bayer new zealand limited - levonorgestrel 75mg (micronised) - subcutaneous implant - 150 mg - active: levonorgestrel 75mg (micronised) excipient: dow corning qcf-7-4910 dimethylsiloxane/methylvinylsiloxane external tubing (373-tw) polysiloxane adhesive type a - long-term contraception

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

bayer new zealand limited - vardenafil 10mg (as vardenafil hydrochloride trihydrate 11.852mg) - film coated tablet - 10 mg - active: vardenafil 10mg (as vardenafil hydrochloride trihydrate 11.852mg) excipient: colloidal silicon dioxide crospovidone hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose titanium dioxide

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

bayer new zealand limited - vardenafil 20mg (as vardenafil hydrochloride trihydrate 23.705mg) - film coated tablet - 20 mg - active: vardenafil 20mg (as vardenafil hydrochloride trihydrate 23.705mg) excipient: colloidal silicon dioxide crospovidone hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose titanium dioxide

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

bayer new zealand limited - vardenafil 5mg (as vardenafil hydrochloride trihydrate 5.926mg) - film coated tablet - 5 mg - active: vardenafil 5mg (as vardenafil hydrochloride trihydrate 5.926mg) excipient: colloidal silicon dioxide crospovidone hypromellose iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose titanium dioxide

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

bayer new zealand limited - meglumine gadopentetate 469 mg/ml (formed from gadolinium oxide, diethylenetriamine pentetic acid & meglumine) - solution for injection - 469 mg/ml - active: meglumine gadopentetate 469 mg/ml (formed from gadolinium oxide, diethylenetriamine pentetic acid & meglumine) excipient: meglumine pentetic acid water for injection

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

bayer new zealand limited - meglumine gadopentetate 469 mg/ml (formed from gadolinium oxide, diethylenetriamine pentetic acid & meglumine) - solution for injection - 469 mg/ml - active: meglumine gadopentetate 469 mg/ml (formed from gadolinium oxide, diethylenetriamine pentetic acid & meglumine) excipient: meglumine pentetic acid water for injection - for diagnostic use by intravenous administration only. cranial and spinal magnetic resonance imaging (mri) in particular for the demonstration of tumours and for further differential-diagnostic clarification in suspected meningioma, (acoustic) neurinoma, invasive tumours (e.g. glioma) and metastases; for the demonstration of small and/or isointense tumours; in suspected recurrence after surgery or radiotherapy; for the differentiated demonstration of rare neoplasms such as haemangioblastomas, ependymomas and small pituitary adenomas; for improved determination of the spread of tumours not of cerebral origin. additionally in spinal mri: differentiation of intra- and extramedullary tumours; demonstration of solid tumour areas in known syrinx; determination of intramedullary tumour spread. whole body mri including the facial skull, the neck region, the thoracic and abdominal space, the female breast, the pelvis and the active and passive locomotive apparatus and imaging of vessels throughout the body. in particular, magnevist permits diagnostic information: · for the demonstration or exclusion of tumours, inflammation and vascular lesions; · for determination of the spread and demarcation of these lesions; · for the differentiation of the internal structure of lesions; · for assessment of the circulatory situation of normal and pathologically changed tissues; · for the differentiation of tumour and scar tissue after therapy; · for the recognition of recurrent prolapse of a disk after surgery. · for the semi-quantitative evaluation of the renal function combined with anatomical organ diagnosis.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ethinylestradiol 20ug; levonorgestrel 100ug - coated tablet - 20µg/100µg - active: ethinylestradiol 20ug levonorgestrel 100ug excipient: calcium carbonate glycerol glycol montanate iron oxide red iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc purified water starch sucrose titanium dioxide calcium carbonate glycol montanate lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc   sucrose - oral contraception

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

bayer new zealand limited - levonorgestrel 52mg - intrauterine contraceptive device - 52 mg - active: levonorgestrel 52mg - contraception

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

bayer new zealand limited - lormetazepam 1mg;   - tablet - 1 mg - active: lormetazepam 1mg   excipient: lactose monohydrate magnesium stearate povidone starch - short-term treatment of insomnia (characterised by difficulty in falling asleep and frequent nocturnal awakenings). noctamid is only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

bayer new zealand limited - gadoxetate disodium 181.43 mg/ml (manufactured in-situ from gadolinium oxide and ethoxybenzyl dtpa) - solution for injection - 181.43 mg/ml - active: gadoxetate disodium 181.43 mg/ml (manufactured in-situ from gadolinium oxide and ethoxybenzyl dtpa) excipient: hydrochloric acid as 3.6% w/w aqueous solution caloxetate complexing agent sodium hydroxide trometamol water for injection - for use in adults for the enhancement of magnetic resonance imaging (mri) of focal liver lesions